Inflammation promotes resistance to immune checkpoint inhibitors in high microsatellite instability colorectal cancer

• Published in: Nature communications Vol. 13; no. 1; p. 7316
• Main Authors: Sui, Qiaoqi, Zhang, Xi, Chen, Chao, Tang, Jinghua, Yu, Jiehai, Li, Weihao, Han, Kai, Jiang, Wu, Liao, Leen, Kong, Lingheng, Li, Yuan, Hou, Zhenlin, Zhou, Chi, Zhang, Chenzhi, Zhang, Linjie, Xiao, Binyi, Mei, Weijian, Xu, Yanbo, Qin, Jiayi, Zheng, Jian, Pan, Zhizhong, Ding, Pei-Rong
• Format: Journal Article
• Language: English
• Published: London Nature Publishing Group UK 28-11-2022; Nature Publishing Group; Nature Portfolio
• Subjects: 13; 13/2; 38; 38/91; 49/39; 631/250/251; 631/250/256; 692/4028/67/1504/1885; 692/4028/67/580; 96/1; Cancer; CD80 antigen; CD86 antigen; Colorectal cancer; Colorectal carcinoma; Colorectal Neoplasms - drug therapy; Colorectal Neoplasms - genetics; CTLA-4 protein; Gene sequencing; Health services; Humanities and Social Sciences; Humans; Immune checkpoint inhibitors; Immune Checkpoint Inhibitors - pharmacology; Immune Checkpoint Inhibitors - therapeutic use; Immune response; Immune status; Immune system; Immunosuppression; Immunosuppressive agents; Inflammation; Inflammation - genetics; Inhibitors; Leukocytes; Leukocytes (neutrophilic); Lymphocytes; Lymphocytes T; Metastases; Microenvironments; Microsatellite Instability; multidisciplinary; Neutrophils; Organoids; Patients; PD-1 protein; Pembrolizumab; Retrospective Studies; Science; Science (multidisciplinary); Tumor Microenvironment - genetics; Tumors
• ISSN: 2041-1723; 2041-1723
• DOI: 10.1038/s41467-022-35096-6

Inflammation is a common medical complication in colorectal cancer (CRC) patients, which plays significant roles in tumor progression and immunosuppression. However, the influence of inflammatory conditions on the tumor response to immune checkpoint inhibitors (ICI) is incompletely understood. Here we show that in a patient with high microsatellite instability (MSI-H) CRC and a local inflammatory condition, the primary tumor progresses but its liver metastasis regresses upon Pembrolizumab treatment. In silico investigation prompted by this observation confirms correlation between inflammatory conditions and poor tumor response to PD-1 blockade in MSI-H CRCs, which is further validated in a cohort of 62 patients retrospectively enrolled to our study. Inhibition of local but not systemic immune response is verified in cultures of paired T cells and organoid cells from patients. Single-cell RNA sequencing suggests involvement of neutrophil leukocytes via CD80/CD86-CTLA4 signaling in the suppressive immune microenvironment. In concordance with this finding, elevated neutrophil-to-lymphocyte ratio indicates inhibited immune status and poor tumor response to ICIs. Receiver operating characteristic curve further demonstrates that both inflammatory conditions and a high NLR could predict a poor response to ICIs in MSI- CRCs, and the predictive value could be further increased when these two predictors are combined. Our study thus suggests that inflammatory conditions in MSI-H CRCs correlate with resistance to ICIs through neutrophil leukocyte associated immunosuppression and proposes both inflammatory conditions and high neutrophil-to-lymphocyte ratio as clinical features for poor ICI response.
Inflammatory conditions often affect colorectal cancer patients, and their effect on their ongoing treatment is a pressing medical question. Here authors show that inflammation interferes with local anti-tumour immune response and inhibits response to immune checkpoint blockade therapy via immunosuppressive neutrophil leukocytes.